← Leaderboards
Christian Mueller
Univ Of Massachusetts Med Sch Worcester
$6,721,276
Attributed
$10,431,103
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2013–20$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$10,431,103 · 5
By mechanism
P01$4,017,888 · 2
R01$3,393,898 · 2
R24$3,019,317 · 1
Top collaborators
- Terence R. Flotte5 shared
- Michael Allen Brehm4 shared
- Robert H Brown4 shared
- Dale L Greiner4 shared
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Jessica Lynn Cohen$158,538
- Sarah Marie Davis$93,062
- Jonathan K Watts$5,302,344
- Craig C. Mello$12,454,719
- Zuoshang Xu$14,371,059
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMediatingProteinsGene TherapyGenesMouse ModelTranslatingTransgenic MiceMutationPhysiologicalSafetyAllelesAlpha 1-AntitrypsinAlpha 1-Antitrypsin DeficiencyLung DiseasesVectorLeadAnimal ModelLiverHepatocyteMutantPhenotypeLiver DiseasesMicrornas
Grant awards (23)
Third generation liver-directed dual-function AAT vectors$502,500
P01 · FY2020 · HL · contact PI
Animal Models Core$306,306
P01 · FY2020 · HL · contact PI
Third generation liver-directed dual-function AAT vectors$502,500
P01 · FY2019 · HL · contact PI
Nuclease free gene editing approaches to treat alpha-1 antitrypsin disease$376,875
R01 · FY2019 · DK · contact PI
Animal Models Core$306,306
P01 · FY2019 · HL · contact PI
Third generation liver-directed dual-function AAT vectors$670,000
P01 · FY2018 · HL · contact PI
Animal Models Core$278,888
P01 · FY2018 · HL · contact PI
Development and Validation of Novel NSG Mouse Models for Human Stem Cell Therapy$725,922
R24 · FY2017 · OD
Silencing C9or72 with rAAV Mediated RNAi$464,134
R01 · FY2017 · NS
Third generation liver-directed dual-function AAT vectors$368,500
P01 · FY2017 · HL · contact PI
Animal Models Core$278,888
P01 · FY2017 · HL · contact PI
Development and Validation of Novel NSG Mouse Models for Human Stem Cell Therapy$764,128
R24 · FY2016 · OD
Third generation liver-directed dual-function AAT vectors$502,500
P01 · FY2016 · HL · contact PI
Dual-function vectors for in vivo gene therapy of AAT Liver disease$364,313
R01 · FY2016 · DK
Silencing C9or72 with rAAV Mediated RNAi$360,494
R01 · FY2016 · NS
Animal Models Core$301,500
P01 · FY2016 · HL · contact PI
Development and Validation of Novel NSG Mouse Models for Human Stem Cell Therapy$748,845
R24 · FY2015 · OD
Dual-function vectors for in vivo gene therapy of AAT Liver disease$364,313
R01 · FY2015 · DK
Silencing C9or72 with rAAV Mediated RNAi$360,494
R01 · FY2015 · NS
Development and Validation of Novel NSG Mouse Models for Human Stem Cell Therapy$780,422
R24 · FY2014 · OD
Silencing C9or72 with rAAV Mediated RNAi$377,369
R01 · FY2014 · NS
Dual-function vectors for in vivo gene therapy of AAT Liver disease$363,950
R01 · FY2014 · DK
Dual-function vectors for in vivo gene therapy of AAT Liver disease$361,956
R01 · FY2013 · DK